The A3-45 trial is researching the safety and effectiveness of an investigational medication in people who might be at increased risk for developing memory loss associated with Alzheimer’s disease. The study is looking for people, age 55-80 years old, who have generally normal memory function in daily life, and who are not being treated for memory problems. For individuals age 55-64 years old, an additional risk factor is required, such as a parent or sibling with Alzheimer’s disease or previous biomarker testing showing increased risk for developing Alzheimer’s disease. Contact Lauren Mackenzie at spearsl@med.umich.edu or 734-232-2415.
